Recombinant human thrombopoietin: basic biology and evaluation of clinical studies

DOI PDF 7 Citations
  • David J. Kuter
    From the Hematology/Oncology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and the Centre for Child Health Research, The University of Western Australia and Western Australian Institute for Medical Research, Perth, Western Australia.
  • C. Glenn Begley
    From the Hematology/Oncology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and the Centre for Child Health Research, The University of Western Australia and Western Australian Institute for Medical Research, Perth, Western Australia.

Abstract

<jats:p>Thrombocytopenia is a common medical problem for which the main treatment is platelet transfusion. Given the increasing use of platelets and the declining donor population, identification of a safe and effective platelet growth factor could improve the management of thrombocytopenia. Thrombopoietin (TPO), the c-Mpl ligand, is the primary physiologic regulator of megakaryocyte and platelet development. Since the purification of TPO in 1994, 2 recombinant forms of the c-Mpl ligand—recombinant human thrombopoietin (rhTPO) and pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF)—have undergone extensive clinical investigation. Both have been shown to be potent stimulators of megakaryocyte growth and platelet production and are biologically active in reducing the thrombocytopenia of nonmyeloablative chemotherapy. However, neither TPO has demonstrated benefit in stem cell transplantation or leukemia chemotherapy. Other clinical studies have investigated the use of TPO in treating chronic nonchemotherapy-induced thrombocytopenia associated with myelodysplastic syndromes, idiopathic thrombocytopenic purpura, thrombocytopenia due to human immunodeficiency virus, and liver disease. Based solely on animal studies, TPO may be effective in reducing surgical thrombocytopenia and bleeding, ex vivo expansion of pluripotent stem cells, and as a radioprotectant. Ongoing and future studies will help define the clinical role of recombinant TPO and TPO mimetics in the treatment of chemotherapy- and nonchemotherapy-induced thrombocytopenia.</jats:p>

Journal

  • Blood

    Blood 100 (10), 3457-3469, 2002-11-15

    American Society of Hematology

Citations (7)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top